Amendment: SEC Form SC 13G/A filed by Revance Therapeutics Inc.
$RVNC
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 5) *
Revance Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
761330109
(CUSIP Number)
September 30, 2024
(Date of the Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed :
|
☐
|
Rule 13d-1(b)
|
|
☒
|
Rule 13d-1(c)
|
|
☐
|
Rule 13d-1(d)
|
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures
provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provision of the Act (however, see the Notes).
|
SCHEDULE 13G
|
|
|
CUSIP No. 761330109
|
Page 2 of 5 Pages
|
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
|
GIC Private Limited
|
|
|
|||
|
|
|
||||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
||||
|
(a)☐
|
|||||
|
(b)☐
|
|
|
|||
|
3
|
SEC USE ONLY
|
|
|
||
| |
|
|
|||
|
|
|
||||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
Republic of Singapore
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
|
0
|
|
|
|||
|
|
|
||||
|
6
|
SHARED VOTING POWER
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
|
☐
|
|
|
|||
|
|
|
||||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
|
0% (1)
|
|
|
|||
|
|
|
||||
|
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
|
CO
|
|
|
|||
|
|
|
||||
|
SCHEDULE 13G
|
|
|
CUSIP No. 761330109
|
Page 3 of 5 Pages
|
| Item 1(a) |
Name of Issuer
|
Revance Therapeutics, Inc.
| Item 1(b) |
Address of Issuer’s Principal Executive Offices
|
1222 Demonbreun Street, Suite 2000
Nashville, Tennessee, 37203
| Item 2(a) |
Name of Persons Filing
|
GIC Private Limited (“GIC”)
| Item 2(b) |
Address of Principal Business Office or, if none, Residence
|
168 Robinson Road
#37-01 Capital Tower
Singapore 068912
| Item 2(c) |
Citizenship
|
Singapore
| Item 2(d) |
Title of Class of Securities
|
Common Stock, par value $0.001 per share
| Item 2(e) |
CUSIP Number
|
761330109
| Item 3 |
If this statement is filed pursuant to §§240.13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
Not applicable.
| Item 4 |
Ownership
|
(a - c) The aggregate number of securities and percentage of the class of securities of the Issuer beneficially owned by the Reporting Person named in Item 2(a), as well as the number of securities as to which such person
is deemed to have sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, shared power to dispose or direct the disposition, is set forth in the following tables:
|
Reporting Person
|
No. of Securities
Beneficially Owned
|
Percent of Class
(1)
|
Voting Power
|
Dispositive Power
|
||
|
Sole (2), (3)
|
Shared (2), (3)
|
Sole (2), (3)
|
Shared (2), (3)
|
|||
|
GIC Private Limited
|
0
|
0
|
0
|
0
|
0
|
0
|
| (2) |
GIC is a fund manager and only has 2 clients – the Government of Singapore (“GoS”) and the Monetary Authority of Singapore (“MAS”). Under the investment management agreement with GoS, GIC has been given the sole discretion to exercise the
voting rights attached to, and the disposition of, any shares managed on behalf of GoS.
|
GIC is wholly-owned by the GoS and was set up with the sole purpose of managing Singapore’s foreign reserves. The GoS disclaims beneficial ownership of such shares
| (3) |
GIC disclaims membership in a group.
|
|
SCHEDULE 13G
|
|
|
CUSIP No. 761330109
|
Page 4 of 5 Pages
|
| Item 5 |
Ownership of Five Percent or Less of a Class
|
If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities,
check the following ☒
| Item 6 |
Ownership of More than Five Percent on Behalf of Another Person
|
Not applicable.
| Item 7 |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
|
Not applicable.
| Item 8 |
Identification and Classification of Members of the Group
|
Not applicable.
| Item 9 |
Notice of Dissolution of Group
|
Not applicable.
| Item 10 |
Certifications
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
|
SCHEDULE 13G
|
|
|
CUSIP No. 761330109
|
Page 5 of 5 Pages
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of dated.
|
GIC PRIVATE LIMITED
|
|||
|
By:
|
/s/ Diane Liang Weishan | ||
|
Name: Diane Liang Weishan
|
|||
|
Title: Senior Vice President
|
|||
|
Date: October 21, 2024
|
|||
|
By:
|
/s/ Toh Tze Meng | ||
|
Name: Toh Tze Meng
|
|||
|
Title: Senior Vice President
|
|||
|
Date: October 18, 2024
|
|||